Cystic Fibrosis: Pathogenesis and Future Treatment Strategies
about
Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosisPseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatmentA template for mutational data analysis of the CFTR gene.Use of kinase inhibitors to correct ΔF508-CFTR function.Activated MCTC mast cells infiltrate diseased lung areas in cystic fibrosis and idiopathic pulmonary fibrosis.F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.Impact of Long-Term Tiotropium Bromide Therapy on Annual Lung Function Decline in Adult Patients with Cystic FibrosisComplex structure of type VI peptidoglycan muramidase effector and a cognate immunity protein.Cysteamine re-establishes the clearance of Pseudomonas aeruginosa by macrophages bearing the cystic fibrosis-relevant F508del-CFTR mutation.Ivacaftor: a review of its use in patients with cystic fibrosis.The development of diabetes among Danish cystic fibrosis patients over the last two decades.A French multicentric study and review of pulmonary Nocardia spp. in cystic fibrosis patients.Pseudomonas aeruginosa Diversification during Infection Development in Cystic Fibrosis Lungs-A Review.Profile of cystic fibrosis in two reference centers in southern Brazil.Nebulized hyaluronan ameliorates lung inflammation in cystic fibrosis mice.Matrine modulates HSC70 levels and rescues ΔF508-CFTR.Down-regulation of cytokine-induced interleukin-8 requires inhibition of p38 mitogen-activated protein kinase (MAPK) via MAPK phosphatase 1-dependent and -independent mechanisms.Vaccine strategies against cystic fibrosis pathogens.Group B streptococcus (GBS) is an important pathogen in human disease- but what about in cystic fibrosis?Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.Phenazine content in the cystic fibrosis respiratory tract negatively correlates with lung function and microbial complexity.Oxidative stress in cystic fibrosis patients with Burkholderia cenocepacia airway colonization: relation of 8-isoprostane concentration in exhaled breath condensate to lung function decline.The burden of lung disease: the need for stem cell therapy--a review series prologue.Discriminating typical and atypical cystic fibrosis-related bacteria by multiplex PNA-FISH.Exercise performance and quality of life in children with cystic fibrosis and mildly impaired lung function: relation with antibiotic treatments and hospitalization.The isoprenoid end product N6-isopentenyladenosine reduces inflammatory response through the inhibition of the NFκB and STAT3 pathways in cystic fibrosis cells.Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study.Association of CFTR gene mutation with bronchial asthma and its severity in Indian children: A case-control study
P2860
Q26765794-480B58F7-9920-40DF-8552-DAD96268C8C7Q33824149-D09A1C58-BF2D-4F31-81BE-5788A3CF559FQ33917285-67C39146-550B-442B-9A9A-0C0C5DD40047Q34304720-36771195-EC6F-428A-8A0A-6E5EF8139B6BQ35531817-129677B2-11A4-4B9B-ADA7-8D24AAF68ABAQ35630919-AC60DF5C-308D-4EE6-BC13-0BABFAF7C6ACQ36063173-A455A230-4C2B-4C03-A22E-5DCB9109002FQ37220564-E3BA21B0-9E6C-4F3B-A9BF-4421E9AADA07Q37744944-827BD07C-8F1C-405D-8E73-F8D9F351543FQ38136994-BC833FD4-5D43-43D2-8FC6-5CC77DCDDF2EQ38217187-32D06121-6E9E-48D2-A531-39488E2A159CQ38262649-FF91CAB7-5617-4FD5-B155-579C4037DC3FQ38273318-29017111-D09A-414F-9B19-47F7485F05FAQ38536798-AC135FF4-9EE4-4308-8FC0-179FCDB34716Q39309260-C6E1CBB3-959D-4580-B182-BA31C11C271DQ39428516-AF2FD25F-7112-4671-961D-8ACBC9110D01Q39567122-1371A293-2C5A-4340-A0D5-E8A0153A6F32Q40262035-FCDA32D3-C2D0-49B3-89CF-893753A01ACDQ41992050-1C445701-793D-4E1B-9C43-CC17DA86E280Q42751920-30DDFB80-67E7-4B3C-8106-09021710FE6FQ45729541-1E77F733-CCF2-40C5-84A1-F8AA2AC97400Q45891399-DDB85DA5-2296-4B5F-A387-F9397D7049A4Q46483421-7872B6A9-CB35-40F2-BEB2-884574532F48Q46495945-3B6F2A50-A5C5-49CA-8E53-80F3C4B3A170Q47255978-39976211-575E-4F08-B475-1B73EE279E81Q48137311-462332C2-C8C9-46E9-AE6C-C48E87C5857EQ53139077-8F3FB2D7-96BE-4E56-934B-B5BD3CDE0825Q58154422-5E3D8768-2592-4759-B598-D65ADCDBDB5B
P2860
Cystic Fibrosis: Pathogenesis and Future Treatment Strategies
description
2009 nî lūn-bûn
@nan
2009 թուականին հրատարակուած գիտական յօդուած
@hyw
2009 թվականին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Cystic Fibrosis: Pathogenesis and Future Treatment Strategies
@ast
Cystic Fibrosis: Pathogenesis and Future Treatment Strategies
@en
Cystic Fibrosis: Pathogenesis and Future Treatment Strategies
@en-gb
type
label
Cystic Fibrosis: Pathogenesis and Future Treatment Strategies
@ast
Cystic Fibrosis: Pathogenesis and Future Treatment Strategies
@en
Cystic Fibrosis: Pathogenesis and Future Treatment Strategies
@en-gb
prefLabel
Cystic Fibrosis: Pathogenesis and Future Treatment Strategies
@ast
Cystic Fibrosis: Pathogenesis and Future Treatment Strategies
@en
Cystic Fibrosis: Pathogenesis and Future Treatment Strategies
@en-gb
P356
P1433
P1476
Cystic Fibrosis: Pathogenesis and Future Treatment Strategies
@en
P2093
Felix A Ratjen
P304
P356
10.4187/AARC0427
P577
2009-01-01T00:00:00Z